Header Logo

Connection

MANDEEP BAJAJ to Hypoglycemic Agents

Back to Details
This is a "connection" page, showing publications MANDEEP BAJAJ has written about Hypoglycemic Agents.
MANDEEP BAJAJ
Connection Strength
3.684
Hypoglycemic Agents
  1. Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study. Diabet Med. 2014 Dec; 31(12):1505-14.
    View in: PubMed
    Score: 0.358
  2. Potential of incretin-based therapies for non-alcoholic fatty liver disease. J Diabetes Complications. 2013 Jul-Aug; 27(4):401-6.
    View in: PubMed
    Score: 0.323
  3. The effect of pioglitazone treatment on 15-epi-lipoxin A4 levels in patients with type 2 diabetes. Atherosclerosis. 2012 Jul; 223(1):204-8.
    View in: PubMed
    Score: 0.308
  4. Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. Diabetologia. 2011 Dec; 54(12):3093-100.
    View in: PubMed
    Score: 0.295
  5. Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes. Obesity (Silver Spring). 2011 Dec; 19(12):2310-5.
    View in: PubMed
    Score: 0.289
  6. Effects of pioglitazone on intramyocellular fat metabolism in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2010 Apr; 95(4):1916-23.
    View in: PubMed
    Score: 0.264
  7. Type 2 diabetes treatment and macrovascular complications--fat and sugar make a dangerous souffl?. Metab Syndr Relat Disord. 2009 Apr; 7(2):79-81.
    View in: PubMed
    Score: 0.248
  8. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus. Diabetologia. 2007 Aug; 50(8):1723-31.
    View in: PubMed
    Score: 0.218
  9. Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus. Expert Opin Pharmacother. 2006 Jun; 7(8):1055-64.
    View in: PubMed
    Score: 0.204
  10. Compounded GLP-1 and Dual GIP/GLP-1 Receptor Agonists: A Statement from the American Diabetes Association. Diabetes Care. 2025 Feb 01; 48(2):177-181.
    View in: PubMed
    Score: 0.186
  11. Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients. Int J Obes Relat Metab Disord. 2004 Jun; 28(6):783-9.
    View in: PubMed
    Score: 0.178
  12. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes. 2003 Jun; 52(6):1364-70.
    View in: PubMed
    Score: 0.166
  13. GLP-1 Receptor Agonists and Cardiovascular Disease: a Meta-Analysis of Recent Cardiac Outcome Trials. Cardiovasc Drugs Ther. 2018 02; 32(1):65-72.
    View in: PubMed
    Score: 0.114
  14. SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor. Cardiovasc Drugs Ther. 2017 Apr; 31(2):119-132.
    View in: PubMed
    Score: 0.108
  15. Aleglitazar, a dual peroxisome proliferator-activated receptor-a and -? agonist, protects cardiomyocytes against the adverse effects of hyperglycaemia. Diab Vasc Dis Res. 2017 03; 14(2):152-162.
    View in: PubMed
    Score: 0.107
  16. Phosphodiesterase-3 inhibition augments the myocardial infarct size-limiting effects of exenatide in mice with type 2 diabetes. Am J Physiol Heart Circ Physiol. 2013 Jan 01; 304(1):H131-41.
    View in: PubMed
    Score: 0.079
  17. GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease. JAMA Intern Med. 2024 Nov 01; 184(11):1314-1323.
    View in: PubMed
    Score: 0.046
  18. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2004 Sep; 89(9):4312-9.
    View in: PubMed
    Score: 0.045
  19. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab. 2004 Jan; 89(1):200-6.
    View in: PubMed
    Score: 0.043
  20. Free fatty acids reduce splanchnic and peripheral glucose uptake in patients with type 2 diabetes. Diabetes. 2002 Oct; 51(10):3043-8.
    View in: PubMed
    Score: 0.040
  21. miR-30a targets gene networks that promote browning of human and mouse adipocytes. Am J Physiol Endocrinol Metab. 2020 10 01; 319(4):E667-E677.
    View in: PubMed
    Score: 0.034
  22. Ubc9 Impairs Activation of the Brown Fat Energy Metabolism Program in Human White Adipocytes. Mol Endocrinol. 2015 Sep; 29(9):1320-33.
    View in: PubMed
    Score: 0.024
  23. Blood glucose awareness training and epinephrine responses to hypoglycemia during intensive treatment in type 1 diabetes. Diabetes Care. 1999 Jul; 22(7):1022-8.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.